Table 3 Clinicopathological and genetic characteristics of Omani CRC cases.
| Â | Omani | Â | Â | Â | Â |
|---|---|---|---|---|---|
| Â | All | non-MSI-H | MSI-H | Odds Ratio | P |
Number of patients | 61 | 53 (87)a | 8 (13)a | Â | Â |
Mean Age | 52.7+13.6 - | 53.1+12.8 - | 51.5+19.2 - | Â | 0.76 |
Gender | Â | Â | Â | Â | 0.37 |
   Female | 24 (39) | 22 (42) | 2 (25) | 1 |  |
   Male | 37 (61) | 31(58) | 6 (75) | 2.12(0.39–11.55) |  |
Site | 61 | Â | Â | Â | 0.75 |
   Distal | 51 (84) | 44(83) | 7(87) | 1 |  |
   Proximal | 10 (16) | 9(17) | 1(13) | 1.43(0.16–13.11) |  |
Mucin Production | 61 | Â | Â | Â | 0.44 |
   None | 47 (77) | 42(78) | 5 (63) | 1 |  |
   < 50% | 14(23) | 11 (20) | 3(37) | 2.3(0.47–11.10) |  |
   > 50% | 0 | 0 | 0 | NA |  |
Differentiation | 60 | Â | Â | Â | 0.44 |
   Well | 7 (12) | 7 (14) | 0 | NA |  |
   Moderate | 49(82) | 43 (81) | 6(86) | 1 |  |
   Poor | 4 (6) | 3 (6) | 1 (14) | 2.39(0.21–26.84) |  |
Stage | 61 | Â | Â | Â | 0.28 |
   Stage 1 | 1 (2) | 1 (2) | 0 | NA |  |
   Stage 2 | 20 (33) | 15 (28) | 5 (62) | 1 |  |
   Stage 3 | 31 (50) | 29 (55) | 2 (25) | 0.21(0.02–1.50) |  |
   Stage 4 | 9 (15) | 8 (15) | 1 (13) | 0.38(0.01–4.41) |  |
BRAF | 59 | Â | Â | Â | 0.62 |
   Wild type | 48 (81) | 42 (82) | 6 (75) | 1 |  |
   V600E | 11 (19) | 9 (18) | 2 (25) | 1.56(0.27–9.0) |  |
hMLH1 methylation (MSP) | 49 | Â | Â | Â | 0.47 |
   Unmethylation | 8 (16) | 6(14.6) | 2 (25) | 1 |  |
   Methylation | 41 (84) | 35 (85.4) | 6 (75) | 0.51(0.08–3.17) |  |
p16 methylation (MSP) | 44 | Â | Â | Â | 0.09 |
   Unmethylation | 27(62) | 20 (56) | 7 (88) | 1 |  |
   Methylation | 17 (38) | 16 (44) | 1 (12) | 0.18(0.02–1.61) |  |
hMLH1 expression by IHC | 61 | Â | Â | Â | 0.68 |
   Normal | 42 (69) | 37(70) | 5 (62) | 1 |  |
   Negative | 19 (32) | 16 (30) | 3(38) | 1.39(0.29–6.67) |  |
hMSH2 expression by IHC | 61 | Â | Â | Â | 0.63 |
   Normal | 56 (92) | 49 (92) | 7(87) | 1 |  |
   Negative | 5 (8) | 4 (8) | 1(13) | 1.75(0.17–16.67) |  |